Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -40.21% is 23% above its 1-year average of -52.14%, near the high end of its 1-year range (-64.06%–-40.21%).
As of the fiscal period ended Wednesday, December 31, 2025. 22.87% above its 12-month average of -52.14%.
Limited history available
ATTO Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
-40.21%
RETURN ON EQUITY (ROE) AVG TTM
-52.14%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+22.87%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 430 covered companies
CURRENT VS SECTOR MEDIAN
-6.77%
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$774.32M
Return on Equity (ROE)
-40.21%
TTM Avg
-52.14%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$775.72M
Return on Equity (ROE)
-35.07%
TTM Avg
-26.66%
3Y Avg
-24.19%
5Y Avg
-5.48%
Market Cap
$776.24M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
Market Cap
$780.95M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$767.46M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
Market Cap
$786.48M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$749.55M
Return on Equity (ROE)
-70.19%
TTM Avg
-78.37%
3Y Avg
-123.45%
5Y Avg
-79.18%
Market Cap
$812.20M
Return on Equity (ROE)
12.32%
TTM Avg
19.75%
3Y Avg
23.44%
5Y Avg
27.16%
Market Cap
$734.10M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $774.32M | -40.21% | -52.14% | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -35.07% | -26.66% | -24.19% | -5.48% |
| Geron Corporation (GERN)vs › | $776.24M | -31.97% | -50.13% | -87.97% | -79.93% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -16.56% | 0.55% | -10.56% | -13.37% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -22.36% | -60.32% | -42.71% | -132.49% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -25.03% | -10.49% | -5.87% | -23.97% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -70.19% | -78.37% | -123.45% | -79.18% |
| InMode Ltd. (INMD)vs › | $812.20M | 12.32% | 19.75% | 23.44% | 27.16% |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -13.30% | 11.91% | 154.09% | 54.89% |
ROE
-40.2%
ROA
-36.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -40.21% |
| 2024-12-31 | -64.06% |
